STOCK TITAN

Tarsus Pharmaceuticals, Inc. (TARS) SEC Filings, Mar 18-19, 2026

TARS NASDAQ

Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.

Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.

Rhea-AI Summary

TARS submitted a Form 144 to sell 2,186 shares of Common stock. The notice lists Fidelity Brokerage Services LLC as broker with a sale date of 03/19/2026. The filing also shows a restricted stock vesting event on 03/18/2026 for 2,186 shares and prior reported sales of 2,111 and 2,133 on 03/17/2026

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Aziz A. Mottiwala files a Form 144 notifying a planned sale of 4,440 shares of Common Stock. The filing links the shares to restricted stock vesting dated 03/18/2026 and records two recent dispositions: 4,286 shares on 03/17/2026 and 4,330 shares on 03/18/2026.

The Form 144 names Fidelity Brokerage Services LLC as the broker-dealer. The filing characterizes the 4,440 shares as compensation-related restricted stock that vested on 03/18/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

TARS filed a Form 144 reporting proposed sales tied to recently vested restricted common stock and recent dispositions by an insider. The filing lists 11,964 shares associated with restricted stock vesting on 03/18/2026 and shows prior sales by Bobak Azamian of 10,972 shares on 03/17/2026 and 11,667 shares on 03/18/2026, with dollar amounts shown alongside each sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Dianne C. Whitfield filed a Form 144 reporting proposed sales of Common Stock. The filing lists three transactions: 15,565 shares on 01/02/2026 (proceeds $1,255,687.45), 4,029 shares on 03/17/2026 (proceeds $279,671.82), and 4,071 shares on 03/18/2026 (proceeds $279,717.60).

The broker on the notice is Fidelity Brokerage Services LLC. The filing includes a separate line noting Restricted Stock Vesting dated 03/18/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

TARS filed a Form 144 reporting proposed sale of 4,231 shares of Common Stock. The filing also records recent dispositions by Bryan Wahl of 4,084 shares on 03/17/2026 and 4,125 shares on 03/18/2026, with dollar entries of 283,489.63 and 283,427.93 respectively.

The notice lists a brokerage holder, Fidelity Brokerage Services LLC, and identifies a 03/18/2026 restricted stock vesting classified as Compensation. This Form 144 is a routine disclosure of intended resale under Rule 144 and related recent insider dispositions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

TARS filed a Form 144 reporting proposed sales of Common Stock by a reporting person. The filing lists 4,589 shares to be sold following a restricted stock vesting on 03/18/2026 as compensation. It also discloses prior sales in March: 8,366, 3,125, and 3,610 shares with associated proceeds reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

TARS reported a Rule 144 notice for the proposed sale of 390 shares of Common Stock tied to a restricted stock vesting on 03/18/2026. The filing lists prior short-term transactions by Elizabeth Yeu-Lin: 375 shares on 03/17/2026 and 379 shares on 03/18/2026.

The filing identifies Fidelity Brokerage Services LLC as the broker and labels the 390-share entry as compensation-related (restricted stock vesting). This notice is an administrative disclosure of an intended resale under Rule 144.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Dianne C. Whitfield filed a Form 144 notice to sell 4,071 shares of Common Stock. The shares are tied to restricted stock vesting dated 03/17/2026 and are listed with Fidelity Brokerage Services LLC as broker. The filing also discloses prior dispositions of 15,565 shares on 01/02/2026 and 4,029 shares on 03/17/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Bryan Wahl filed a Form 144 to offer 4,125 shares of Common Stock. The filing links the shares to a restricted stock vesting event dated 03/17/2026 and lists Fidelity Brokerage Services LLC as the broker. The filing also shows recent activity of 4,084 shares sold on 03/17/2026 and includes adjacent amounts $283,427.93 and $283,489.63.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Bobak Azamian reports proposed sale of common stock under Rule 144. The filing lists 11,667 common shares associated with Fidelity Brokerage Services LLC on 03/18/2026. The filing also discloses a prior sale of 10,972 shares on 03/17/2026 for $761,618.09.

The securities to be sold are listed as resulting from restricted stock vesting and are labeled compensation on 03/17/2026. Timing and exact sale methods are not detailed in the excerpt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

How many Tarsus Pharmaceuticals (TARS) SEC filings are available on StockTitan?

StockTitan tracks 139 SEC filings for Tarsus Pharmaceuticals (TARS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Tarsus Pharmaceuticals (TARS)?

The most recent SEC filing for Tarsus Pharmaceuticals (TARS) was filed on March 19, 2026.